The Clinical Pharmacogenetics Implementation Consortium (CPIC) issues guidelines that are designed to help clinicians and patients alike to understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and preemptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients’ genotypes available even if they have not explicitly ordered a test with a specific drug in mind.
CPIC assigns levels of pharmacogenetic evidence to pairs of genes and related drugs according to (1) PharmGKB Clinical Annotation Levels of Evidence of 1A, 1B, 2A and 2B, or (2) a PharmGKB PGx level for FDA-approved drug labels of i) “actionable pgx”, ii) “genetic testing recommended”, or iii) “genetic testing required”, or (3) based on nomination to CPIC for consideration.
thasso provides here the table below, in which links to each Guideline will take you to a webpage where you can download the guideline manuscript, supplement and any other related files. There, you will also find information about when the guideline was published and the most recent update of the guideline. Other links in the table will take you to more information on the PharmGKB website.